Euclid Phoenix Lens Design Trial 2

NCT ID: NCT06392607

Last Updated: 2024-04-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-31

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lens wettability and subjective comfort of Euclid orthokeratology lenses with and without an enhanced coating will be compared in 50 children. Axial elongation will be monitored in pediatric patients who qualify and consent.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this trial is to provide an assessment of the lens wettability and patient comfort with an enhanced surface treatment for the Emerald Lens design when used by practitioners with moderate experience with fitting Euclid orthokeratology lenses.

The hypothesis to be tested is that the proportion of participants with a lens wettability score of \> 3 (on a 5 point scale) with the enhanced surface treatment will be greater than that of the current lens surface, using a 1 to 5 scale

The primary outcome variable is lens wettability as measured on eye using a 1 to 5 scale

This clinical investigation will be a prospective, randomized, double-masked two-arm non-crossover trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia Cornea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Euclid orthokeartology (standard coating)

Euclid Orthokeratology Contact Lenses are lathe cut contact lenses with spherical posterior surfaces. The posterior curve is selected to properly fit an individual eye for orthokeratology and the anterior curve is selected to provide the necessary optical power for a temporary reduction of myopia. A peripheral curve system on the posterior surface allows tear exchange between the lens and the cornea.

Group Type EXPERIMENTAL

Euclid orthokeratology (standard coating)

Intervention Type DEVICE

Lens with the current coating

Euclid orthokeartology (enhanced coating)

Euclid Orthokeratology Contact Lenses are lathe cut contact lenses with spherical posterior surfaces. The posterior curve is selected to properly fit an individual eye for orthokeratology and the anterior curve is selected to provide the necessary optical power for a temporary reduction of myopia. A peripheral curve system on the posterior surface allows tear exchange between the lens and the cornea.

Group Type EXPERIMENTAL

Euclid orthokeratology (enhanced coating)

Intervention Type DEVICE

Lens with the enhanced coating

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Euclid orthokeratology (standard coating)

Lens with the current coating

Intervention Type DEVICE

Euclid orthokeratology (enhanced coating)

Lens with the enhanced coating

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be of legal age or, if under legal age have written consent of their parent or guardian to participate.
* Sign written Informed Consent (and the California Bill of Rights, if applicable).
* Ages 6-35 (inclusive) and able to understand and assent to participation
* Current wearers of Euclid Emerald (Oprifocon A) Orthokeratology lenses, which at initiation of fitting, had

* Need of optical correction for myopia, from -1.00 to -5.00 Diopters (D).
* Refractive astigmatism of less than -1.50 D.
* Have a minimum Best Spectacle Corrected Visual Acuity (BSCVA) of 20/40 or better in each eye.
* Have acceptable or optimal fit with study lenses (once fitting has been completed) and be willing to wear these lenses as directed for the duration of the study.
* On examination, have ocular findings considered to be within normal limits, including:

* No evidence of active infection involving the conjunctiva, lids or adnexa.
* No evidence of structural abnormalities of the lid, conjunctiva or adnexal tissue considered significant by the investigator to include minimum levels (Grade 2 or less) of tarsal-conjunctival abnormalities
* Clear corneas with no evidence of edema, staining, opacities, corneal neovascularization greater than a trace amount (i.e. All vessels extending less than 1.5 mm from the limbus); all as observed on slit lamp examination.
* No iritis.
* No herpes keratitis (recurrent or otherwise) or other active ocular disease that would contraindicate lens wear or lessen attainability of VA sought in this study (20/40 or better).
* No evidence of dry eye or meibomian gland dysfunction
* Normal binocularity (no amblyopia or strabismus, and no anisometropia of greater than 2.00D)
* Be willing and able to follow instructions and attend the schedule of follow-up visits.

* Not able or willing to provide informed consent and assent
* Requires concurrent ocular medication
* Eye injury or surgery within twelve weeks immediately prior to enrollment
* Pre-existing ocular condition that would preclude contact lens fitting
* Currently enrolled in an ophthalmic clinical trial
* Pregnant or lactating or expect to become pregnant during the trial
* Evidence of systemic or ocular abnormality, infection or disease likely to affect successful wear of contact lenses or use of their accessory solutions.
* Allergy or sensitivity to any product used in this trial
* Any systemic disease including autoimmune disease, immunocompromising diseases, connective tissue disease, clinically significant atopic diseases, insulin dependent diabetes, use of medications including corticosteroids and antimetabolites that may affect the eye or be exaggerated by contact lenses.
* Strabismus/amblyopia
* Habitual uncorrected anisometropia ≥ 2.00D
* Subjects who have undergone corneal refractive surgery
* Subjects with severe corneal irregularity contraindicating lens wear
* Inability to wear contact lenses, or an unacceptable contact lens fit
* Poor or unacceptable fit with any study lens
* Employees, staff or family members of personnel at the site
Minimum Eligible Age

6 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Euclid Systems Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cornea and Contact Lens Institute of Minnesota

Edina, Minnesota, United States

Site Status

Pinecone Vision Center

Sartell, Minnesota, United States

Site Status

Somerset Eye Care

North Brunswick, New Jersey, United States

Site Status

Southern College of Optometry

Memphis, Tennessee, United States

Site Status

Specialty Eyecare Group

Kirkland, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sally Dillehay, OD, EdD

Role: CONTACT

Phone: 7705214358‬

Email: [email protected]

Brett O'Connor, OD

Role: CONTACT

Phone: 9048947427

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Zachary Holland

Role: primary

Trevor Fosso, OD

Role: primary

Tobin Ansel

Role: primary

Chris Lievens

Role: primary

David Kading

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EU-PHX-RCT-002

Identifier Type: -

Identifier Source: org_study_id